bluebird bio
NEWS
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Winter and the Holidays are right around the corner, but don’t stop your job search! Check out the top companies who are looking for candidates like you right now!
Janssen Pharmaceutical, a Johnson & Johnson company, along with Legend Biotech, reported results from their LEGEND-2 Phase I/II clinical trial of CAR-T therapy LCAR-B38M. The therapeutic was being investigated in patients with advanced relapsed or refractory (r/r) multiple myeloma.
At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.
The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.
With the American Society of Hematology (ASH) Annual Meeting held this weekend, Celgene and its various collaboration partners had several important presentations.
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!
JOBS
IN THE PRESS
99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at up to 21 months post-treatment
Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3052538.
bluebird bio, Inc. and Forty Seven, Inc. announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with bluebird’s ex vivo lentiviral vector hematopoietic stem cell gene therapy platform.
Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma
Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline
Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020.
First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now available to be manufactured in the European Union
bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia.
bluebird bio, Inc. announced that it has appointed William R. Sellers, M.D. to its Board of Directors.
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.